Australia - English - Department of Health (Therapeutic Goods Administration)

gedeon richter australia pty ltd - relugolix, quantity: 40 mg; estradiol, quantity: 1 mg (equivalent: estradiol hemihydrate, qty 1.032 mg); norethisterone acetate, quantity: 0.5 mg - tablet, film coated - excipient ingredients: mannitol; sodium starch glycollate type a; magnesium stearate; lactose monohydrate; hyprolose; titanium dioxide; hypromellose; triacetin; iron oxide yellow - ryeqo is indicated in adult women of reproductive age for:,? treatment of moderate to severe symptoms of uterine fibroids,,?symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis (see section 5.1 pharmacodynamic properties).

United States - English - NLM (National Library of Medicine)

nelco laboratories, inc. - apple (unii: b423vgh5s9) (apple - unii:b423vgh5s9) - apple 0.1 g in 1 ml - allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. the use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. allergenic extracts should not be used if the patient has asthma, cardiovascular disease, emphysema, diabetes, bleeding diathesis or pregnancy, unless a specific diagnosis of t

United States - English - NLM (National Library of Medicine)

nelco laboratories, inc. - apple (unii: b423vgh5s9) (apple - unii:b423vgh5s9) - apple 0.05 g in 1 ml - allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. the use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. allergenic extracts should not be used if the patient has asthma, cardiovascular disease, emphysema, diabetes, bleeding diathesis or pregnancy, unless a specific diagnosis of t

United States - English - NLM (National Library of Medicine)

nelco laboratories, inc. - apple (unii: b423vgh5s9) (apple - unii:b423vgh5s9) - allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. the use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. allergenic extracts should not be used if the patient has asthma, cardiovascular disease, emphysema, diabetes, bleeding diathesis or pregnancy, unless a specific diagnosis of t

United States - English - NLM (National Library of Medicine)

nelco laboratories, inc. - apple (unii: b423vgh5s9) (apple - unii:b423vgh5s9) - allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. the use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. allergenic extracts should not be used if the patient has asthma, cardiovascular disease, emphysema, diabetes, bleeding diathesis or pregnancy, unless a specific diagnosis of t

European Union - English - EMA (European Medicines Agency)

gedeon richter plc. - relugolix, norethisterone acetate, estradiol hemihydrate - leiomyoma - pituitary and hypothalamic hormones and analogues - ryeqo is indicated in adult women of reproductive age for:- treatment of moderate to severe symptoms of uterine fibroids,- symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

allergopharma - rye flour allergen extract - solution for skin-prick test

United States - English - NLM (National Library of Medicine)

alk-abello, inc. - potato (unii: cfe1s8dywd) (potato - unii:cfe1s8dywd) - potato 0.1 mg in 1 ml - these products are for diagnostic use only. diagnostic allergenic extracts are indicated for use in skin testing to establish the clinical relevance of specific allergens to which the patient has been exposed. by measuring skin test response the physician may assess the degree of sensitivity that patients have to the allergens. for extracts standardized in au and bau, see individual directions for use. allergenic extracts for diagnostic use only of coffee, mosquito, cottonseed, and flaxseed have not been shown by adequate data to be safe and effective for therapeutic use. patients on beta blockers can be non-responsive to beta agonists that may be required to reverse a systemic reaction (also, see boxed warning statement and adverse reactions ). the physician should carefully weigh the benefit derived from skin testing vs. the risk to the patient should a systemic reaction arise. patients with unstable asthma or steroid dependent asthmatics and patients with underlying cardiovascular disease are at greater r

United States - English - NLM (National Library of Medicine)

jubilant hollisterstier llc - bos taurus hair (unii: toq97z8644) (bos taurus hair - unii:toq97z8644), bos taurus dander (unii: c8vys726o8) (bos taurus dander - unii:c8vys726o8) - equus caballus hair 0.01 g in 1 ml - non-standardized allergenic extracts are indicated for: - skin test diagnosis of individuals with a clinical history of allergy to the specific corresponding allergens. non-standardized allergenic extracts are indicated for: - immunotherapy for the reduction of allergen-induced allergic symptoms confirmed by positive skin test or by in vitro testing for allergen specific ige antibodies for the specific corresponding allergens. non-standardized allergenic extracts are contraindicated in individuals with the following conditions: - severe, unstable or uncontrolled asthma. - history of any severe systemic reaction to the allergen extract when administered for diagnosis or treatment. - medical conditions that reduce the ability to survive anaphylaxis. risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes.  in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respecti

United States - English - NLM (National Library of Medicine)

antigen laboratories, inc. - pea (unii: w4x7h8gyfm) (pea - unii:w4x7h8gyfm) - pea 0.05 g in 1 ml - allergenic extract is used for diagnostic testing and for the treatment (immunotherapy) of patients whose histories indicate that upon natural exposure to the allergen, they experience allergic symptoms. confirmation is determined by skin testing. diagnostic use of allergenic extracts usually begins with direct skin testing. this product is not intended for treatment of patients who do not manifest immediate hypersensitivity reactions to the allergenic extract following skin testing. do not administer in the presence of diseases characterized by bleeding diathesis. individuals with autoimmune disease may be at risk of exacerbating symptoms of the underlying disease, possibly due to routine immunization. patients who have experienced a recent myocardial infarction may not be tolerant of immunotherapy. children with nephrotic syndrome probably should not receive injections due to immunization causing exacerbation of nephrotic disease.